Petition to the FDA to Require a Warning About a Dangerous Drug Interaction Between Clopidogrel (Plavix) and Repaglinide (Prandin) in the Label for Both Drugs
December 28, 2016, Acknowledgement letter from the FDA.
August 7, 2017, final response letter from the FDA
Public Citizen petitions the Food and Drug Administration (FDA) to require that the labels of the anti-clotting drug clopidogrel (Plavix) and the diabetes drug repaglinide (Prandin) warn doctors and patients that taking the drugs together can cause dangerously low blood sugar levels. The petition also asks that the drugs’ labels include a statement that the two drugs should never be taken together under any circumstances.